licensing

News

Ipsen doubles up in TCEs for cancer, adding Biomunex drug

Ipsen has expanded its oncology pipeline by licensing a T cell engager (TCE) therapy from Paris-based startup Biomunex for up to $610m.

News

Woman pushing man in wheelchair along beachfront as sun sets

Novartis pays $1bn upfront for Huntington's drug from PTC

Novartis has made a return to the Huntington's disease stage by licensing an oral mRNA splicer from PTC Therapeutics for $1 billion upfront.

News

MSD joins PD-1/VEGF push in cancer with LaNova deal

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy.

News

Ono, Boehringer add to cancer pipelines with licensing deals

Ono Pharma and Boehringer Ingelheim both added to their cancer pipelines, licensing drugs from LigaChem Bio and Circle Pharma, respectively.

News

AZ extends cardiovascular pipeline with $2bn CSPC deal

AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceut

News

Lungs computer graphic in palm of a doctor's hand

Roivant's new 'vant' emerges to advance Bayer lung drug

Roivant's latest biotech company launch – Pulmovant – has made its debut with a plan to develop a respiratory drug licensed from Bayer in a deal worth up to $294 million.

Ipsen doubles up in TCEs for cancer, adding Biomunex drug

Novartis pays $1bn upfront for Huntington's drug from PTC

MSD joins PD-1/VEGF push in cancer with LaNova deal

Ono, Boehringer add to cancer pipelines with licensing deals

AZ extends cardiovascular pipeline with $2bn CSPC deal

Roivant's new 'vant' emerges to advance Bayer lung drug

CHMP decision levels the playing field for GSK's RSV jab

How to meet your physicians where they are online

licensing

Editor's Picks